Drug intelligence / Profile preview

mTa-CAR-T cells

Development stage: Preclinical
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intratumoral

Overview

mTa-CAR-T cells are engineered T cells designed to target the tumor microenvironment (TME) and induce Tertiary Lymphoid Structures (TLS). These cells are constructed with a membrane-tethered anti-Lymphotoxin-beta receptor (LTβR) single-chain variable fragment (Sc-Fv) alongside a Chimeric Antigen Receptor (CAR) construct. By functioning as lymphoid tissue inducer cells (LTi) and interacting with lymphoid tissue organizer cells (LTo) that express LTβR, mTa-CAR-T cells aim to nucleate TLS within aggressive tumors like glioblastoma multiforme (GBM). The induction of TLS is hypothesized to make the TME more immune-permissive, thereby enhancing the efficacy of CAR-T therapy and improving patient survival.

Targets

TNFR (TNF receptor family)

Beyond the preview

Go deeper on mTa-CAR-T cells.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on mTa-CAR-T cells.

Explore the full profile